BeiGene's Brukinsa US Application For Expanded Use Under FDA Review

The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application for Brukinsa (zanubrutinib) for marginal zone lymphoma (MZL) and granted priority review.
The application covers adult MZL patients who have received at least one prior anti-CD20-based therapy.
The agency's target action date is September 19.
Brukinsa is a small molecule inhibitor of Bruton's tyrosine kinase to treat various B-cell malignancies.
Price Action: BGNE shares closed at $337.98 on Tuesday.

To add Benzinga News as your preferred source on Google, click here.

The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application for Brukinsa (zanubrutinib) for marginal zone lymphoma (MZL) and granted priority review.
The application covers adult MZL patients who have received at least one prior anti-CD20-based therapy.
The agency's target action date is September 19.
Brukinsa is a small molecule inhibitor of Bruton's tyrosine kinase to treat various B-cell malignancies.
Price Action: BGNE shares closed at $337.98 on Tuesday.

To add Benzinga News as your preferred source on Google, click here.